DNA damage in IDH-mutant gliomas: mechanisms and clinical implications
暂无分享,去创建一个
[1] R. Deberardinis,et al. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma , 2022, Cancer cell.
[2] R. Koche,et al. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burden , 2022, bioRxiv.
[3] Christine C. Hudson,et al. Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. , 2021, Cancer discovery.
[4] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[5] S. Heiland,et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas , 2021, Nature Cancer.
[6] D. Maucort-Boulch,et al. Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI). , 2021 .
[7] W. Mason,et al. Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas. , 2021 .
[8] K. Aldape,et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. , 2021, The Lancet. Oncology.
[9] M. Snuderl,et al. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. , 2021, Journal of neuropathology and experimental neurology.
[10] T. Jiang,et al. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma , 2021, Cancer biology & medicine.
[11] Jennie W. Taylor,et al. Abstract 2046: Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment , 2020 .
[12] H. Wakimoto,et al. Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells. , 2020, Cancer discovery.
[13] J. Shay,et al. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. , 2020, Cancer cell.
[14] P. Glazer,et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling , 2020, Nature.
[15] E. Maher,et al. INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. , 2020 .
[16] B. Shuch,et al. Oncometabolites suppress DNA repair by disrupting local chromatin signaling , 2020, Nature.
[17] J. Huse,et al. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas , 2020, Science Advances.
[18] Raymond Y Huang,et al. Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.
[19] T. Richardson,et al. Total copy number variation, somatic mutation burden, and histologic grade correlate with clinical outcome in oligodendroglioma. , 2020, Clinical neuropathology.
[20] M. Snuderl,et al. Total copy number variation as a prognostic factor in adult astrocytoma subtypes , 2019, Acta Neuropathologica Communications.
[21] Christian M. Metallo,et al. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma , 2018, Cell.
[22] M. Weller,et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate , 2018, Nature Medicine.
[23] C. Marosi,et al. Correlation of immune phenotype with IDH mutation in diffuse glioma , 2017, Neuro-oncology.
[24] A. Iafrate,et al. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. , 2017, Cancer research.
[25] A. M. Houghton,et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas , 2017, Genes & development.
[26] J. Costello,et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.
[27] M. Gilbert,et al. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. , 2017, Cancer research.
[28] Gregory A. Breuer,et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.
[29] C. Perou,et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. , 2015, Cell reports.
[30] A. Iafrate,et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer cell.
[31] Shawn M. Gillespie,et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.
[32] W. Vandertop,et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. , 2015, Cancer research.
[33] Susan M. Chang,et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.
[34] Jing Chen,et al. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation , 2015, Tumor Biology.
[35] Caterina Giannini,et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[37] W. Kaelin,et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.
[38] Benjamin L. Ebert,et al. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.
[39] S. Mulholland,et al. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations , 2012, International journal of cancer.
[40] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[41] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[42] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[43] Magnar Bjørås,et al. Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA , 2003, Nature.
[44] P. Bates,et al. Reversal of DNA alkylation damage by two human dioxygenases , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[45] S. Shibata,et al. Protective Role of Glutathione Synthesis on Radiation-Induced DNA Damage in Rabbit Brain , 1998, Cellular and Molecular Neurobiology.
[46] A. Meister. Glutathione, ascorbate, and cellular protection. , 1994, Cancer research.
[47] Cairncross,et al. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design , 2021 .
[48] Zachary,et al. Oncometabolites Dand L-2-hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions , 2017 .
[49] J. Uhm. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .
[50] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2010, Nature.
[51] Zhao,et al. IDH 1R 132 H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response , 2022 .